Kura Oncology Inc (NASDAQ:KURA) major shareholder Ecor1 Capital Fund Qualified, acquired 40,538 shares of the company’s stock in a transaction dated Thursday, December 13th. The shares were bought at an average price of $13.90 per share, for a total transaction of $563,478.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ecor1 Capital Fund Qualified, also recently made the following trade(s):

  • On Thursday, December 6th, Ecor1 Capital Fund Qualified, bought 119,906 shares of Kura Oncology stock. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $1,618,731.00.

NASDAQ KURA opened at $14.03 on Friday. Kura Oncology Inc has a twelve month low of $10.20 and a twelve month high of $24.02. The company has a quick ratio of 14.76, a current ratio of 14.76 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.01. On average, equities research analysts anticipate that Kura Oncology Inc will post -1.72 earnings per share for the current fiscal year.

A number of research firms recently weighed in on KURA. BidaskClub cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Piper Jaffray Companies set a $25.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research note on Monday, December 3rd. ValuEngine cut shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 19th. Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Monday, October 22nd. Finally, Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.86.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc boosted its position in Kura Oncology by 2.1% in the third quarter. Vanguard Group Inc now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after buying an additional 29,785 shares in the last quarter. Vanguard Group Inc. boosted its position in Kura Oncology by 2.1% in the third quarter. Vanguard Group Inc. now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after buying an additional 29,785 shares in the last quarter. Teachers Advisors LLC boosted its position in Kura Oncology by 20.1% in the third quarter. Teachers Advisors LLC now owns 51,013 shares of the company’s stock valued at $893,000 after buying an additional 8,536 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in Kura Oncology by 111.6% in the third quarter. MetLife Investment Advisors LLC now owns 21,375 shares of the company’s stock valued at $374,000 after buying an additional 11,273 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Kura Oncology by 185.1% in the third quarter. Point72 Asset Management L.P. now owns 377,952 shares of the company’s stock valued at $6,614,000 after buying an additional 245,406 shares in the last quarter. Hedge funds and other institutional investors own 79.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Kura Oncology Inc (KURA) Major Shareholder Buys $563,478.20 in Stock” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/insider-buying-kura-oncology-inc-kura-major-shareholder-buys-563478-20-in-stock/2689643.html.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Book Value Per Share in Stock Trading

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.